- Why A Change In A Bristol-Myers Hepatitis C Trial Has Big Implications
Is a promising new class of drugs for treating hepatitis C going to be limited because patients with the most common genotype of the virus are likely to develop resistance to the medications? This is the possibility raised by a Wall Street analyst after learning that Bristol-Myers Squibb has altered the protocol for a clinical trial for its daclatasvir antiviral, which is believed to be the most potent in the forthcoming NS5a class of hepatitis c treatments. null, responseDetails: Suspected Terms of Service Abuse. Please see responseStatus: 40
- Apple Won't Let Kaspersky Develop Tools For iOS
This sounds like a slightly strange decision by Apple: they'll not let Kaspersky develop anti-viral tools for iOS. Kaspersky himself thinks that this is one of the things that will enable Google's Android to leapfrog Apple. There are going to be some infections or malware at some point and without preparation such could be disastrous.
Eugene Kaspersky is “a little bit disappointed … Apple won’t let us” develop antivirus software for iOS devices, as he feels it is only a matter of time before criminals target the operating system. null, responseDetails: Suspected Terms of Service Abuse. Please see responseStatus: 40
- Cyber war between Qihoo, Tencent easing
The clash between two Chinese tech giants appeared to be subsiding Wednesday after Qihoo 360, a leading online security software provider, said that Tencent's popular instant messaging platform QQ was running smoothly on computers that also had their antivirus software.
However, Tencent, China's largest Internet firm by market capitalization, said that 5 million QQ users, still using Koukou Guard, a downloadable tool promoted by 360 as the solution to stop the illegal scanning by blocking ... ハイテク大手中国の衝突の間に2つ、プロバイダは、ソフトウェアのセキュリティを買うリードすること沈降水曜日後Qihoo 360、登場ソフトウェアをウイルス対策の一般的なインスタントメッセージングのTencentの言ったことがあったまた、コンピュータのプラットフォームQQをしていた実行してスムーズに
- Storage & Norton In Focus As Symantec Aims For $22
Symantec plans to report Q2 earnings today. We look at updates in its main business divisions of enterprise storage software and Norton Antivirus that accounts for around 75% of its valuation. シマンテックは、今日は第2四半期収益を報告する予定です
- Symantec Heads to $20 with Antivirus And Storage Combo
Symantec announced its Q1 results last week that showed solid revenues growth of 15% to$1.6 billion. Its two most important business segments ? Storage & Server Management and Consumer Products (Norton), which comprise almost 75% of the Trefis price estimate for Symantec ? reported steady revenue growth for the quarter despite strong competition from McAfee by Intel and Microsoft in the security segment as well as EMC, IBM, NetApp and Hewlett-Packard in storage software.
We have revised our Trefis price estimate to about $20 following the earnings release implying around 10% upside to the current market price. シマンテックは16億ドルに15％の固体収入の伸びを示した先週の第1四半期の結果を発表しました
- Norton Vaults Above $22 As Android Mobile Security Market Booms
Symantec is the largest maker of security software for computers. Norton Antivirus software is a major revenue driver for the company and comprises almost 34% of the Trefis price estimate for Symantec. シマンテックでは、コンピュータのセキュリティソフトの最大のメーカーです
- Symantec Comes Out Swinging For Market Share, Stock Good For $21
Symantec is the global leader in the security software market, and sells a number of products to consumers and enterprises. Some of the products include the Norton line of antivirus products for consumers, and it also offers data loss prevention and data encryption products for enterprises. In the consumer antivirus market, Symantec competes with McAfee, now part of by Intel, as well as Microsoft, CA, AVG, TrendMicro and Kaspersky Labs. シマンテックは、セキュリティソフトウェア市場におけるグローバルリーダーであり、消費者や企業への製品の数を販売しています
- 「Microsoft Security Essentials」公開1週間で150万本ダウンロード
「「microsoft security essentials」公開1週間で150万本ダウンロード
- Ad-Aware Free Antivirus +
⇒ ad-aware free antivirus + - ダウンロード
⇒ ad-awareの使い方
他のウィルス対策ソフトと、競合する可能性があるかも
- Pharma firm Bristol-Myers Squibb to buy Inhibitex
Pharmaceutical giant Bristol-Myers Squibb Company announced it was acquiring Inhibitex, Inc., a company specializing in treatment of hepatitis C, for $2.5 billion (1.9 billion euros).The transaction has been approved by the boards of directors of both companies, the Saturday announcement said.Inhibitex has been focusing on development of nucleotide medicines designed for treatment of hepatitis C.Its lead product under development, known as INX-189, has displayed potent antiviral abilities, experts said. null, responseDetails: Suspected Terms of Service Abuse. Please see responseStatus: 40
- Lords Of Kings Hack Norton Antivirus, Are You Safe?
Symantec, one of the largest computer security firms in the world, seems to need urgent help with computer security. There are reports that Symantec has confirmed that hackers have stolen a portion of its popular flagship product Norton Antivirus. null, responseDetails: Suspected Terms of Service Abuse. Please see responseStatus: 40
|
